Cargando…

TYROSINEMIA TYPE III: A CASE REPORT OF SIBLINGS AND LITERATURE REVIEW

OBJECTIVE: Tyrosinemia type III (HT III) is the rarest form of tyrosinemia, and the full clinical spectrum of this disorder is still unknown. The neurological involvement varies, including intellectual impairment and attention deficit disorder with hyperactivity (ADHD). We report the case of two sib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barroso, Fábio, Correia, Joana, Bandeira, Anabela, Carmona, Carla, Vilarinho, Laura, Almeida, Manuela, Rocha, Júlio César, Martins, Esmeralda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade de Pediatria de São Paulo 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274528/ https://www.ncbi.nlm.nih.gov/pubmed/32520295 http://dx.doi.org/10.1590/1984-0462/2020/38/2018158

Ejemplares similares

Iron‐sulfur cluster ISD11 deficiency (LYRM4 gene) presenting as cardiorespiratory arrest and 3‐methylglutaconic aciduria
por: Coelho, Margarida Paiva, et al.
Publicado: (2019)

Tyrosinemia type III in an asymptomatic girl
por: Szymanska, Edyta, et al.
Publicado: (2015)

Metabolic Control of Patients with Phenylketonuria in a Portuguese Metabolic Centre Comparing Three Different Recommendations
por: Kanufre, Viviane, et al.
Publicado: (2021)

Implementing a Transition Program from Paediatric to Adult Services in Phenylketonuria: Results after Two Years of Follow-Up with an Adult Team
por: Peres, Maria, et al.
Publicado: (2021)

Hepatorenal tyrosinemia
por: KITAGAWA, Teruo
Publicado: (2012)

A Case of Tyrosinemia Type III with Status Epilepticus and Mental Retardation
por: Najafi, Reza, et al.
Publicado: (2018)

The mutation spectrum and ethnic distribution of non-hepatorenal tyrosinemia (types II, III)
por: Beyzaei, Zahra, et al.
Publicado: (2022)

Syndrome of hereditary tyrosinemia in mink
por: Christensen, K, et al.
Publicado: (1978)

Leigh Syndrome Spectrum: A Portuguese Population Cohort in an Evolutionary Genetic Era
por: Baldo, Manuela Schubert, et al.
Publicado: (2023)

Over Restriction of Dietary Protein Allowance: The Importance of Ongoing Reassessment of Natural Protein Tolerance in Phenylketonuria
por: Pinto, Alex, et al.
Publicado: (2019)

Comment on Pancreatitis in Type 1 Tyrosinemia
por: Rahmoune, Hakim, et al.
Publicado: (2017)

Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents
por: Mosca, Sara, et al.
Publicado: (2022)

Type 1 tyrosinemia in Finland: a nationwide study
por: Äärelä, Linnea, et al.
Publicado: (2020)

Neonatal hyperinsulinism in transient and classical forms of tyrosinemia
por: Sethuram, Swathi, et al.
Publicado: (2021)

Treatment adherence in tyrosinemia type 1 patients
por: González-Lamuño, Domingo, et al.
Publicado: (2021)

SLC35A2-CDG: Novel variant and review
por: Quelhas, Dulce, et al.
Publicado: (2021)

Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective
por: Pena, Maria João, et al.
Publicado: (2021)

Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts
Publicado: (1985)

Protein Degradation and the Pathologic Basis of Phenylketonuria and Hereditary Tyrosinemia
por: Sarodaya, Neha, et al.
Publicado: (2020)

Adenine base editing in an adult mouse model of tyrosinemia
por: Song, Chun-Qing, et al.
Publicado: (2019)

Novel Mutation of Tyrosinemia in a Child With Hypophosphatemic Rickets
por: Dogra, Surabhi, et al.
Publicado: (2022)

Case report: ADHD and prognosis in tyrosinemia type 1
por: Barone, Helene, et al.
Publicado: (2023)

LEIGH SYNDROME: A CASE REPORT WITH A MITOCHONDRIAL DNA MUTATION
por: Lopes, Tânia, et al.
Publicado: (2018)

Phenylketonuria in Portugal: Genotype–phenotype correlations using molecular, biochemical, and haplotypic analyses
por: Ferreira, Filipa, et al.
Publicado: (2021)

Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1
por: van Ginkel, Willem G., et al.
Publicado: (2019)

Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia
por: HONAR, Naser, et al.
Publicado: (2017)

Severe neurological crisis in adult patients with Tyrosinemia type 1
por: Dawson, Charlotte, et al.
Publicado: (2020)

Revisiting hereditary tyrosinemia Type 1—spectrum of radiological findings
por: Shaikh, Sana, et al.
Publicado: (2018)

Casein Glycomacropeptide: An Alternative Protein Substitute in Tyrosinemia Type I
por: Daly, Anne, et al.
Publicado: (2021)

Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study
por: Megdadi, Noor A., et al.
Publicado: (2021)

In vivo quantitative photoacoustic evaluation of the liver and kidney pathology in tyrosinemia
por: Huang, Guojia, et al.
Publicado: (2022)

Clinical and Para Clinical Findings in the Children with Tyrosinemia Referring for Liver Transplantation
por: Dehghani, Seyed Mohsen, et al.
Publicado: (2013)

Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls
por: van Ginkel, Willem G., et al.
Publicado: (2016)

Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain
por: Couce, María Luz, et al.
Publicado: (2019)

Therapeutic Targeting of Fumaryl Acetoacetate Hydrolase in Hereditary Tyrosinemia Type I
por: Gil-Martínez, Jon, et al.
Publicado: (2021)

Clinical experience with hepatorenal tyrosinemia from a single Egyptian center
por: El-Karaksy, Hanaa, et al.
Publicado: (2022)

Identification of Novel Mutations in FAH Gene and Prenatal Diagnosis of Tyrosinemia in Indian Family
por: Sheth, Jayesh J., et al.
Publicado: (2012)

Photophobia accompanied by painful plantar punctate hyperkeratotic patches: Tyrosinemia type 2
por: Mohite, Ajay Anand, et al.
Publicado: (2018)

Plantar keratoderma: a manifestation of tyrosinemia type II (Richner-Hanhart Syndrome)
por: Al-Ratrout, Jihad T., et al.
Publicado: (2005)

Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)
por: Das, Anibh Martin
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_11khqt45s2r0slh9ej35r4lco4